Extended indication Adult patients with anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) who have be
Therapeutic value No judgement
Total cost 3,375,000.00

Product

Active substance Brigatinib
Domain Oncology and Hematology
Main indication Lung cancer
Extended indication Adult patients with anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) who have been previously treated with crizotinib.
Proprietary name Alunbrig
Manufacturer Takeda
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date March 2017
Expected Registration 2018
Orphan drug No

Therapeutic value

Current treatment options Ceritinib
Therapeutic value No judgement
Duration of treatment Average 6 month / months
Frequency of administration 1 times a day
Dosage per administration 180 mg
References Fabrikant; Kim et al. J Clin Oncol 34, 2016 (suppl; abstr 9007).

Expected patient volume per year

Patient volume

20 - 70

Market share is generally not included unless otherwise stated.

References Fabrikant
Additional remarks Fabrikant: Max. patiëntvolume: Van 9289 patiënten met NSCLC (IKNL, 2016), is 53% stadium IIIb/IV (4923, IKNL, Kankerzorg in beeld, 2014). Hiervan is 4% ALK+ (197, NVMO CieBOM, Apr 2016). Aannemende dat 70% getest wordt (138), 20% van de ALK+ patiënten geïncludeerd wordt in studies, en 80% van de resterende patiënten crizotinib ontvangt zijn er jaarlijks 88 patiënten op crizotinib. Als 80% hiervan een volgende lijn ontvangt is er een potentieel van 71 patiënten. Van max. naar realistisch patiëntvolume: Ceritinib is reeds beschikbaar voor deze groep. Aangenomen aandeel van 30%.

Expected cost per patient per year

Cost 70,000.00 - 80,000.00
References Medicijnkosten.nl
Additional remarks Gebaseerd op kosten crizotinib (€95,58 per 250 mg) en alectinib (€27,36 per 150 mg).

Potential total cost per year

Total cost

3,375,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.